Syngene International

Bangalore, IN
Biologics Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
63.0
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (2)

Quick Facts: Syngene International

Signal Score
63.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Bangalore, IN
Modalities
Biologics, Cell Therapy
Active CGT Programs
No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-20)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Biocon
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Biocon
SEC FilingsParent: Biocon
Parent company: Biocon
Financial assessment: 68.0/100
Capacity 58.0
1 CGT manufacturing site: Bangalore, IN
Modalities: Biologics, Cell Therapy
Capacity assessment: 60.0/100
Sites: Bangalore, IN
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press2 articles
1 CGT manufacturing site: Bangalore, IN
Modalities: Biologics, Cell Therapy
Capacity assessment: 60.0/100

FDA Inspection History

2025-02
NAI VAI OAI
Date Site Type Observations Classification
2025-02-20 Bengaluru Drug Quality Assurance No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Recent News 2 articles

regulatory 2026-03-11
Indian CDMO Stocks See Mixed Fortunes Amid High Valuations - Whalesbook
Indian CDMO Stocks See Mixed Fortunes Amid High Valuations  Whalesbook
Source →
partnership 2026-02-19
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure - BioSpace
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure  BioSpace
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics CDMOs → Cell Therapy CDMOs →